Federated Hermes Kaufmann Fund Files Intent to Sell $3.39M in Minerva Neurosciences Stock
NERV has more than doubled off its 52-week low of $1.15 on elevated volume (3.5× avg).
Summary
Federated Hermes Kaufmann Fund, a 10% stockholder, filed a Form 144 indicating its intent to sell 424,278 shares of Minerva Neurosciences common stock, valued at approximately $3.39 million.
Key Events · Ownership and Investor Activity · NERV
-
Intent to Sell Shares
Federated Hermes Kaufmann Fund, a 10% stockholder, filed a Form 144 to sell 424,278 shares of common stock.
-
Significant Transaction Value
The proposed sale has an approximate market value of $3.39 million.
-
Institutional Investor Activity
This filing indicates a potential reduction in holdings by a major institutional investor, following a similar filing from a related fund today.
Analysis · NERV · Life Sciences
This Form 144 signals a significant potential reduction in stake by a major institutional investor. While the sale is for liquidity or portfolio rebalancing purposes typical of a 10% owner, the proposed value of $3.39 million represents a notable transaction for Minerva Neurosciences. Investors should monitor for actual sales, as a large block sale could create near-term selling pressure. This follows another Form 144 filing from a related Federated Hermes fund earlier today.
At the time of this filing, NERV was trading at $7.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $343.6M. The 52-week trading range was $1.15 to $12.46. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.